Class Action Filed Against Intellia Therapeutics, Inc. (NTLA) Seeking Recovery for Investors - Contact Levi & Korsinsky
Portfolio Pulse from
A class action lawsuit has been filed against Intellia Therapeutics alleging securities fraud between July 30, 2024 and January 8, 2025. The lawsuit claims the company misled investors about its NTLA-3001 study for alpha-1 antitrypsin deficiency, failing to disclose declining demand for viral-based editing. On January 9, 2025, Intellia announced halting the NTLA-3001 research and reducing workforce by 27%, causing its stock price to drop from $12.02 to $10.20.
March 26, 2025 | 11:45 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Intellia Therapeutics announced discontinuation of NTLA-3001 program and 27% workforce reduction, triggering potential legal action and stock price volatility.
The lawsuit and program cancellation directly impact Intellia's stock, suggesting potential negative short-term market sentiment and investor confidence.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100